Shattuck Labs, Inc. (NASDAQ:STTK) Stock Has Average Price Target of $13.70

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been assigned an average rating of “Buy” from the thirteen analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and three have assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $13.70.

STTK has been the subject of several research reports. Leerink Partners initiated coverage on Shattuck Labs in a research report on Monday, July 20th. They set an “outperform” rating and a $16.00 price target for the company. Wall Street Zen cut shares of Shattuck Labs from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright reduced their target price on shares of Shattuck Labs from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Wedbush raised their price target on shares of Shattuck Labs from $11.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, October 2nd. Finally, Raymond James Financial assumed coverage on shares of Shattuck Labs in a research report on Monday, August 24th. They set a “strong-buy” rating and a $18.00 price target on the stock.

Shattuck Labs Trading Down 0.9%

STTK stock opened at $5.37 on Tuesday. Shattuck Labs has a 12-month low of $1.72 and a 12-month high of $8.33. The stock has a market cap of $538.93 million, a price-to-earnings ratio of -10.53 and a beta of 1.09. The business’s 50-day moving average is $6.58 and its 200 day moving average is $6.51.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). As a group, equities analysts forecast that Shattuck Labs will post -0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in shares of Shattuck Labs during the 2nd quarter worth approximately $41,000. State of Wyoming acquired a new stake in shares of Shattuck Labs in the second quarter valued at approximately $151,000. OMERS ADMINISTRATION Corp increased its holdings in shares of Shattuck Labs by 25.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 33,300 shares of the company’s stock valued at $214,000 after purchasing an additional 6,800 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Shattuck Labs in the first quarter valued at approximately $269,000. Finally, Bank of America Corp DE purchased a new position in Shattuck Labs during the second quarter worth approximately $319,000. 58.74% of the stock is owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create biologic medicines that combine immune checkpoint blockade with immune-cell activation in a single therapeutic construct.

Shattuck’s pipeline has included investigational ARC fusion proteins intended to alter the tumor microenvironment and stimulate immune responses against cancer cells.